<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5685704</article-id><article-id pub-id-type="publisher-id">21113</article-id><article-id pub-id-type="doi">10.18632/oncotarget.21113</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Marcq</surname><given-names>Elly</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Waele</surname><given-names>Jorrit De</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Audenaerde</surname><given-names>Jonas Van</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lion</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Santermans</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hens</surname><given-names>Niel</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pauwels</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Meerbeeck</surname><given-names>Jan P.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A6"><sup>6</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Smits</surname><given-names>Evelien L.J.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="author-notes" rid="FN1">*</xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Center for Oncological Research, University of Antwerp, Antwerp, Belgium</aff><aff id="A2"><sup>2</sup> Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium</aff><aff id="A3"><sup>3</sup> Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium</aff><aff id="A4"><sup>4</sup> Center for Health Economics Research and Modelling Infectious Diseases, University of Antwerp, Antwerp, Belgium</aff><aff id="A5"><sup>5</sup> Department of Pathology, Antwerp University Hospital, Antwerp, Belgium</aff><aff id="A6"><sup>6</sup> Thoracic Oncology/MOCA, Antwerp University Hospital, Antwerp, Belgium</aff><author-notes><fn id="FN1"><label>*</label><p><text><SENT sid="1" pm="."><plain>Shared senior authors </plain></SENT>
</text></p></fn><corresp id="cor1"><bold>Correspondence to:</bold> Elly Marcq, <email>Elly.Marcq@uantwerpen.be</email></corresp></author-notes><pub-date pub-type="collection"><day>27</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>21</day><month>9</month><year>2017</year></pub-date><volume>8</volume><issue>52</issue><fpage>89722</fpage><lpage>89735</lpage><history><date date-type="received"><day>21</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © 2017 Marcq et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License 3.0</ext-link> (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. </plain></SENT>
<SENT sid="3" pm="."><plain>Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. </plain></SENT>
<SENT sid="4" pm="."><plain>Research on the immunological aspects of the easily accessible mesothelioma microenvironment could identify prognostic and/or predictive biomarkers and provide useful insights for developing effective immunotherapy. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>In this context, we investigated the immune cell composition of effusions (pleural and ascites fluids) from 11 different chemotherapy-treated MPM patients. </plain></SENT>
<SENT sid="6" pm="."><plain>We used multicolor flow cytometry to describe different subsets of immune cells and their expression of immune checkpoint molecules TIM-3, LAG-3, PD-1 and PD-L1. </plain></SENT>
<SENT sid="7" pm="."><plain>We demonstrate a patient-dependent inter- and intraspecific variation comparing pleural and ascites fluids in immune cell composition and immune checkpoint expression. </plain></SENT>
<SENT sid="8" pm="."><plain>We found CD4+ and CD8+ T cells, B cells, macrophages, natural killer cells, dendritic cells and tumor cells in the fluids. </plain></SENT>
<SENT sid="9" pm="."><plain>To the best of our knowledge, we are the first to report TIM-3 and LAG-3 expression and we confirm PD-1 and PD-L1 expression on different MPM effusion-resident immune cells. </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, we identified two MPM effusion-related factors with clinical value: CD4+ T cells were significantly correlated with better response to chemotherapy, while the percentage of PD-L1+ podoplanin (PDPN)+ tumor cells is a significant prognostic factor for worse outcome. </plain></SENT>
<SENT sid="11" pm="."><plain>Our data provide a basis for more elaborate research on MPM effusion material in the context of treatment follow-up and prognostic biomarkers and the development of immune checkpoint-targeted immunotherapy. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>mesothelioma</kwd><kwd>immune checkpoints</kwd><kwd>effusions</kwd><kwd>tumor microenvironment</kwd><kwd>flow cytometry</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="12" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Malignant pleural mesothelioma (MPM) is a highly aggressive and fatal cancer that is most commonly associated with asbestos exposure [1]. </plain></SENT>
<SENT sid="14" pm="."><plain>Due to differences in asbestos contact, MPM incidence varies not only between but also within countries [2]. </plain></SENT>
<SENT sid="15" pm="."><plain>Although it used to be a rare disease, its incidence has been increasing in recent years and it is expected to continue in the next decades. </plain></SENT>
<SENT sid="16" pm="."><plain>This is mainly due to an ongoing asbestos use in developing countries, as well as the long latency period between asbestos exposure and the development of disease [3]. </plain></SENT>
<SENT sid="17" pm="."><plain>MPM is characterized by a bad prognosis. </plain></SENT>
<SENT sid="18" pm="."><plain>Palliative platinum-antifolate chemotherapy has a significant but limited impact on patients’ outcome with a median overall survival of about one year [4, 5]. </plain></SENT>
<SENT sid="19" pm="."><plain>Based on this poor prognosis and the increasing incidence, novel therapeutic strategies for MPM are urgently required. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Preliminary clinical evidence suggests a critical role for the immune system in protection against MPM [6–8] and recent promising clinical results have been reported on inhibition of the immune checkpoints cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) or its ligand PD-L1 in MPM [9–14]. </plain></SENT>
<SENT sid="21" pm="."><plain>It is postulated that blocking immune checkpoints reactivates silenced immune responses by preventing immune cell exhaustion and tolerance. </plain></SENT>
<SENT sid="22" pm="."><plain>Gaining more insight in the immunological aspect of the tumor microenvironment (TME) is of great interest in order to identify biomarkers and to unravel these silenced immune responses in order to identify possible new targets for MPM treatment. </plain></SENT>
<SENT sid="23" pm="."><plain>Therefore, we previously investigated the immune composition and the expression of immune checkpoints in human MPM tissue samples [15]. </plain></SENT>
<SENT sid="24" pm="."><plain>Now, we want to focus on pleural and peritoneal effusions. </plain></SENT>
<SENT sid="25" pm="."><plain>These effusions are often present in MPM patients [3] and are easily collected via thoracocentesis or paracentesis. </plain></SENT>
<SENT sid="26" pm="."><plain>Tumor cells and immune cells have been described to be present in pleural effusions [3, 16]. </plain></SENT>
<SENT sid="27" pm="."><plain>Extensive investigation of the cellular composition in relation to the expression of immune checkpoints could help to identify prognostic markers in the effusions. </plain></SENT>
<SENT sid="28" pm="."><plain>It could also provide useful information on immunomodulatory molecules that are expressed in the TME potentially dampening the antitumor immune responses, helping forward the development of novel targeted therapies. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>The few studies on effusions of mesothelioma patients mainly report on the presence of a limited array of immune cells, being CD4+ and CD8+ T cells and macrophages [17–20]. </plain></SENT>
<SENT sid="30" pm="."><plain>One of those studies also describes the expression of PD-1 and PD-L1 [18], but to the best of our knowledge nothing has been described about the expression of T cell immunoglobulin mucin-3 (TIM-3) and lymphocyte activation gene-3 (LAG-3) in mesothelioma effusions. </plain></SENT>
<SENT sid="31" pm="."><plain>The latter two are upcoming immune checkpoints that are gaining more attention due to interesting preclinical results in different tumor types [21–25] and ongoing clinical trials testing specific blocking antibodies (NCT01968109; NCT02817633). </plain></SENT>
<SENT sid="32" pm="."><plain>LAG-3 is expressed on the surface of activated T cells. </plain></SENT>
<SENT sid="33" pm="."><plain>It also binds to MHCII molecules expressed on antigen presenting cells but in contrast to CD4, LAG-3 exerts a negative regulatory effect on the proliferation and activation of T lymphocytes [21, 22]. </plain></SENT>
<SENT sid="34" pm="."><plain>Expression of TIM-3 and its ligand galectin-9 has been described on several immune cells and galectin-9 can also be overexpressed by cancer cells [26, 27]. </plain></SENT>
<SENT sid="35" pm="."><plain>Interaction of TIM-3 with galectin-9 results in decreased immune cell functioning and even immune cell death. </plain></SENT>
<SENT sid="36" pm="."><plain>We have recently described the absence of LAG-3 and the presence of TIM-3 on tumor cells and stromal immune cells in mesothelioma tissue [15]. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>In this study, we characterized the cellular composition and TIM-3, LAG-3, PD-1 and PD-L1 immune checkpoint expression of pleural and ascites fluid samples collected from MPM patients at least one month after chemotherapy treatment. </plain></SENT>
<SENT sid="38" pm="."><plain>Relating to patients’ outcome and response to chemotherapy, we identified two effusion-related factors with clinical value. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="s2"><title><text><SENT sid="39" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec id="s2_1"><title><text><SENT sid="40" pm="."><plain>Immune cell composition of MPM effusions is variable and patient-dependent </plain></SENT>
</text></title><p><text><SENT sid="41" pm="."><plain>Flow cytometry was used to analyze the immune cell composition in five ascites fluids and six pleural fluids collected from MPM patients at least one month after chemotherapy treatment. </plain></SENT>
<SENT sid="42" pm="."><plain>All cell types analyzed could be detected in the fluids with a variable distribution (Table 1). </plain></SENT>
<SENT sid="43" pm="."><plain>Predominant cells were CD3+CD4+ T cells, CD64+ macrophages and CD11c+ or CD303+ dendritic cells (DCs) with percentages up to 51.7%, 38.8% and 43.4% of viable cells, respectively. </plain></SENT>
<SENT sid="44" pm="."><plain>CD3+CD8+ T cells, CD3-CD56+ natural killer (NK) cells and CD19+ B cells were less present, with maxima of 16.9%, 13.5% and 2.9% viable cells per sample. </plain></SENT>
<SENT sid="45" pm="."><plain>Based on the expression of podoplanin (PDPN), a marker for MPM tumor cells [28–31], ascites fluids contained slightly more PDPN+ tumor cells compared to pleural fluids (median 0.5% vs 0.1%). </plain></SENT>
<SENT sid="46" pm="."><plain>Higher percentages of immune cells were noted in the ascites fluids compared to the pleural fluid samples, with p-values ranging from 0.247 to 0.930 (Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title><text><SENT sid="47" pm="."><plain>Immune composition of pleural and ascites fluid samples from MPM patients </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>CD4+ T CELLS (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>CD8+ T CELLS (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>NK CELLS (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>DCs (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>B CELLS (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>MACROPHAGES (%) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>TUMOR CELLS (%) </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="8" align="left" valign="middle" rowspan="1"><text><SENT sid="55" pm="."><plain>Pleural fluid </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>Sample 1 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>2.98 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>1.23 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>1.10 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>36.97 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>0.30 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>17.00 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>0.58 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>Sample 2 (S) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>2.99 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>0.80 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>0.04 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>0.59 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>1.21 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>0.46 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>0.02 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>Sample 3 (S) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>31.16 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>5.84 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>0.83 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>4.09 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>1.77 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>3.31 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>0.04 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>Sample 4 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>4.45 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>0.91 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>0.09 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>0.67 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>0.40 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>0.46 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>0.02 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Sample 5 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>33.83 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>2.45 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>1.27 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>16.77 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>2.86 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>15.70 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>0.11 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>Sample 6 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>29.41 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>7.71 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>2.41 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>27.33 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>1.72 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>26.03 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>0.26 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>MEDIAN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>16.93 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>1.84 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>0.96 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>10.43 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>1.47 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>9.50 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>0.08 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>SD </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>15.41 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>2.92 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>0.88 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>15.28 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>0.96 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>10.62 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>0.22 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>RANGEMIN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>2.99 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>0.80 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>0.04 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>0.67 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>0.30 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>0.46 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>0.02 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>RANGEMAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>33.83 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>7.71 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>2.41 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>36.97 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>2.86 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>26.03 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>0.60 </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="middle" rowspan="1"><text><SENT sid="136" pm="."><plain>Ascites fluid </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>Sample 1 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>20.47 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>2.78 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>2.35 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>12.26 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>1.27 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>11.20 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>0.53 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>Sample 2 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>4.15 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>1.95 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>0.35 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>43.43 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>0.43 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>38.80 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>12.86 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Sample 3 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>51.75 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>11.83 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>0.85 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>12.60 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>2.07 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>11.87 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>0.54 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>Sample 4 (E) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>18.12 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>16.88 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>13.48 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>28.17 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>0.78 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>24.57 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>0.86 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>Sample 5 (N) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>0.80 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>0.79 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>0.05 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>0.06 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>0.05 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>0.06 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>0.01 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>MEDIAN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>18.12 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>2.78 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>0.85 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>12.60 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>0.78 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>11.87 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>0.54 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>SD </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>20.17 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>7.12 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>5.69 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>16.78 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>0.78 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>14.83 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>5.54 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>RANGEMIN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>0.80 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>0.79 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>0.35 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>0.06 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>0.05 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>0.06 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>0.01 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>RANGEMAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>51.75 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>16.88 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>13.48 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>43.43 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>2.07 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>38.80 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>12.86 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="209" pm="."><plain>All percentages are calculated within the total population of viable cells. </plain></SENT>
<SENT sid="210" pm="."><plain>E, epitheloid; S, sarcomatoid; N, no data. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec id="s2_2"><title><text><SENT sid="211" pm="."><plain>Inter and intra sample type variation of PD-1, TIM-3 and LAG-3 expression </plain></SENT>
</text></title><p><text><SENT sid="212" pm="."><plain>The immune checkpoints PD-1, LAG-3 and TIM-3 were expressed on CD3+CD4+ T cells, CD3+CD8+ T cells and on NK cells in both fluid types. </plain></SENT>
<SENT sid="213" pm="."><plain>PD-1 expression was found in all samples on CD8+ T cells and in ten samples on CD4+ T cells and/or NK cells. </plain></SENT>
<SENT sid="214" pm="."><plain>Positivity of LAG-3 was seen in nine samples on CD4+ T cells, in seven samples on CD8+ T cells and in eight samples on NK cells. </plain></SENT>
<SENT sid="215" pm="."><plain>Expression of TIM-3 was observed in all samples on CD4+ T cells and NK cells and in nine samples on CD8+ T cells (Figure 1). </plain></SENT>
<SENT sid="216" pm="."><plain>Figure 1 and Table 2 depict the distributions and proportions of PD-1, LAG-3 and TIM-3 expression on CD3+CD4+ and CD3+CD8+ T cells and NK cells. </plain></SENT>
<SENT sid="217" pm="."><plain>All pleural samples were positive for PD-1 on all three cell types, whereas PD-1 was expressed on CD8+ T cells and NK cells in four of the five ascites samples. </plain></SENT>
<SENT sid="218" pm="."><plain>PD-1 positivity varied in each cell type, ranging from 9% to 61.9% for the CD4+ T cells, 11.4% to 66.4% for the CD8+ T cells and 3.28% to 64.3 % for the NK cells. </plain></SENT>
<SENT sid="219" pm="."><plain>LAG-3+ cells were detected in a higher proportion of pleural fluids compared to ascites fluids. </plain></SENT>
<SENT sid="220" pm="."><plain>LAG-3 expression on a per cell-base, is highest on NK cells in both fluid types. </plain></SENT>
<SENT sid="221" pm="."><plain>A wide range of LAG-3 expression per cell type was recorded, from 1.3–47.6% LAG-3+ CD4+ T cells, 1.1–49.5% LAG-3+ CD8+ T cells and 1.0–68.1% LAG-3+ NK cells (Table 2). </plain></SENT>
<SENT sid="222" pm="."><plain>TIM-3 was expressed on most of the NK cells while less CD3+CD4+ and CD3+CD8+ T cells were positive (Figure 1). </plain></SENT>
<SENT sid="223" pm="."><plain>Based on the difference in mean fluorescence intensity (ΔMFI) values, the highest expression per cell was seen on NK cells. </plain></SENT>
<SENT sid="224" pm="."><plain>Like PD-1 and LAG-3, the proportion of TIM-3+ positive cells varied strongly, illustrated by 5.7–51.6% TIM-3+CD4+ T cells, 5.9–59.7% TIM-3+CD8+ T cells and 13.3–83.6% TIM-3+ NK cells (Figure 1). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title><text><SENT sid="225" pm="."><plain>T cell and NK cell immune checkpoint surface expression in MPM pleural and ascites fluids </plain></SENT>
</text></title><p><text><SENT sid="226" pm="."><plain>Surface expression of PD-1, LAG-3 and TIM-3 on CD3+CD4+ T cells, CD3+CD8+ T cells and CD3-CD56+ NK cells from five ascites (·) and six pleural (▲) fluids. </plain></SENT>
<SENT sid="227" pm="."><plain>Percentages of marker-positive cells were determined using the overton subtraction tool in the FlowJo software. </plain></SENT>
<SENT sid="228" pm="."><plain>The bar represents the median value within all samples. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-89722-g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title><text><SENT sid="229" pm="."><plain>Immune checkpoint expression of MPM effusion-resident immune cells </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>CD4+ T CELLS </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>CD8+ T CELLS </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>NK CELLS </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="5" align="left" valign="middle" rowspan="1"><text><SENT sid="233" pm="."><plain>Pleural fluids (n = 6) </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="234" pm="."><plain>PD-1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>6/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>6/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>6/6 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>772–4902 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>1032–7066 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>763–3932 </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="243" pm="."><plain>LAG-3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>5/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>5/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>5/6 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>61–1221 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>60–7311 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>231–14819 </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="252" pm="."><plain>TIM-3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>6/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>5/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>6/6 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>91–1539 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>1225–5996 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>1297–12541 </plain></SENT>
</text></td></tr><tr><td colspan="5" align="left" valign="middle" rowspan="1"><text><SENT sid="261" pm="."><plain>Ascites fluids (n = 5) </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="262" pm="."><plain>PD-1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>5/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>4/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>4/5 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>689– 4981 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>783–6009 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>215–4708 </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="271" pm="."><plain>LAG-3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>3/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>2/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>3/5 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>154–867 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>208–230 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>36–1410 </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="280" pm="."><plain>TIM-3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>5/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>4/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>5/5 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>368–5194 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>338–6706 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>3036–9595 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="289" pm="."><plain>Variation in the intensity of expression is shown by the range of Δ MFI values. </plain></SENT>
<SENT sid="290" pm="."><plain>MFI, Mean Fluorescence Intensity. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec id="s2_3"><title><text><SENT sid="291" pm="."><plain>PD-1 ligand-1 expression is highest on PDPN+ tumor cells </plain></SENT>
</text></title><p><text><SENT sid="292" pm="."><plain>PD-1 ligand-1, PD-L1, expression was detected on DCs, B cells, macrophages and PDPN+ MPM tumor cells in all ascites samples, while in pleural samples PD-L1 expression varied per cell type (Figure 2, Table 3). </plain></SENT>
<SENT sid="293" pm="."><plain>Positivity of PD-L1 on DCs was found in all samples, while positivity of PD-L1 on B cells was found in nine samples and ten samples showed expression of PD-L1 on macrophages and PDPN+ tumor cells. </plain></SENT>
<SENT sid="294" pm="."><plain>Highest PD-L1 expression was found on the PDPN+ tumor cells in both fluid types, with a median expression of 19.4% PD-L1+ cells and a range of 20 up to 14524 on a per cell basis (Table 3). </plain></SENT>
<SENT sid="295" pm="."><plain>Similar to the immune checkpoints, there is a broad range of PD-L1 positivity between and within the fluid types. </plain></SENT>
<SENT sid="296" pm="."><plain>In ascites fluid samples, more PD-L1+ DCs (p = 0.052) and PD-L1+ macrophages (p = 0.052) were present compared to the pleural fluid samples. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title><text><SENT sid="297" pm="."><plain>Expression of PD-L1 on immune cells and tumor cells in pleural and ascites fluids of MPM patients </plain></SENT>
</text></title><p><text><SENT sid="298" pm="."><plain>Data of eleven different patient samples are shown: five ascites (·) and six pleural (▲) fluids. </plain></SENT>
<SENT sid="299" pm="."><plain>Percentages of marker-positive cells were determined using the overton subtraction tool in the FlowJo software. </plain></SENT>
<SENT sid="300" pm="."><plain>The bar represents the median value within all samples. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-89722-g002"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title><text><SENT sid="301" pm="."><plain>Overview of PD-L1 expression on immune cells and MPM tumor cells in eleven different MPM fluid samples </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>DCs </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>B CELLS </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>MACROPHAGES </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>TUMOR CELLS </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="6" align="left" valign="middle" rowspan="1"><text><SENT sid="306" pm="."><plain>Pleural fluid </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1"><text><SENT sid="307" pm="."><plain>PD-L1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>6/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>4/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>5/6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>5/6 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>305–749 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>9–1684 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>128–972 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>20–14524 </plain></SENT>
</text></td></tr><tr><td colspan="6" align="left" valign="middle" rowspan="1"><text><SENT sid="318" pm="."><plain>Ascites fluid </plain></SENT>
</text></td></tr><tr><td rowspan="2" align="left" valign="middle" colspan="1"><text><SENT sid="319" pm="."><plain>PD-L1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>Positive samples (%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>5/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>5/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>5/5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>5/5 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>ΔMFI rangeMIN-MAX </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>159–1296 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>10–477 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>331–1801 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>955–2679 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="330" pm="."><plain>Variation in the intensity of expression is shown by the range of ΔMFI values. </plain></SENT>
<SENT sid="331" pm="."><plain>MFI, Mean Fluorescence Intensity. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec id="s2_4"><title><text><SENT sid="332" pm="."><plain>Expression of immune checkpoints is correlated with immune cell activation </plain></SENT>
</text></title><p><text><SENT sid="333" pm="."><plain>We investigated correlations between immune cell types expressing immune checkpoints. </plain></SENT>
<SENT sid="334" pm="."><plain>Expression of PD-1, TIM-3 and LAG-3 on CD4+ T cells was correlated with their expression on CD8+ T cells [spearman correlation coefficient (ρs) = 0.74, p = 0.013; ρs = 0.87, p &lt; 0.001; ρs = 0.89, p &lt; 0.001, respectively; Figure 3]. </plain></SENT>
<SENT sid="335" pm="."><plain>TIM-3 and LAG-3 expression was also correlated with CD4+ T cells and NK cells (ρs = 0.66, p = 0.031; ρs = 0.81, p = 0.003, respectively). </plain></SENT>
<SENT sid="336" pm="."><plain>For LAG-3 but not TIM-3, expression on CD8+ T cells was also strongly correlated with its expression on NK cells (ρs = 0.94, p &lt; 0.001). </plain></SENT>
<SENT sid="337" pm="."><plain>For the PD-1 ligand PD-L1, a positive correlation was found for its expression on DCs and macrophages (ρs = 0.77, p = 0.008, Figure 3). </plain></SENT>
<SENT sid="338" pm="."><plain>PD-1, LAG-3 and TIM-3 expression was also put in relation with an activated phenotype of CD3+CD4+, CD3+CD8+ T cells and CD3-CD56+ NK cells, assessed by CD69 expression. </plain></SENT>
<SENT sid="339" pm="."><plain>CD69 expression was significantly correlated with the expression of PD-1 and TIM-3 on CD3+CD8+ T cells (ρs = 0.65, p = 0.037; ρs = 0.77, p = 0.005; Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title><text><SENT sid="340" pm="."><plain>Correlation between immune checkpoint expression on different immune cells and immune cell activation </plain></SENT>
</text></title><p><text><SENT sid="341" pm="."><plain>Significant correlations between immune checkpoint expression on different subsets of immune cells as well as immune cell activation are depicted on the scatter plots. </plain></SENT>
<SENT sid="342" pm="."><plain>Spearman correlation (ρs) coefficients and corresponding p-values are shown for each correlation. </plain></SENT>
<SENT sid="343" pm="."><plain>The lines represent linear regression fits. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-89722-g003"/></fig></SecTag></sec><sec id="s2_5"><title><text><SENT sid="344" pm="."><plain>Patient-matched MPM tissue and effusion samples show specific cell and immune checkpoint expression </plain></SENT>
</text></title><p><text><SENT sid="345" pm="."><plain>Matched tissue and effusion samples from four patients allowed us to compare their immune cell composition and immune checkpoint expression. </plain></SENT>
<SENT sid="346" pm="."><plain>Immunohistochemistry on paraffin-embedded diagnostic tissue samples [15] and multi-parameter flow cytometry on pleural fluids (vide Materials and methods) was assessed for the presence of CD4+ and CD8+ T cells and macrophages and the expression of PD-L1 on tumor cells and PD-L1, LAG-3 and TIM-3 on lymphocytes. </plain></SENT>
<SENT sid="347" pm="."><plain>Patient-matched comparison indicates that the immune composition and immune checkpoint expression differs between the sample types (Supplementary Table 1). </plain></SENT>
<SENT sid="348" pm="."><plain>Higher percentages of macrophages and lymphocytes were noted in the tissue samples compared to the fluid samples. </plain></SENT>
<SENT sid="349" pm="."><plain>We also observed an inter sample type variation in immune checkpoint expression on lymphocytes and PD-L1 expression on tumor cells present in the fluid and tissue samples. </plain></SENT>
</text></p></sec><sec id="s2_6"><title><text><SENT sid="350" pm="."><plain>Two MPM effusion-related cellular parameters with clinical value </plain></SENT>
</text></title><p><text><SENT sid="351" pm="."><plain>Searching for parameters with a potent clinical value, univariate analysis indicates that there is a significant correlation between CD3+CD4+ T cells in MPM effusions after chemotherapy [Mc Fadden's pseudo coefficient of determination (R) = 0.63, p = 0.033]. </plain></SENT>
<SENT sid="352" pm="."><plain>More specifically, partial/complete response to cisplatin/pemetrexed-based chemotherapy was more often noted in patients with high percentages of CD4+ T cells [odds ratio (OR) = 1.13; Figure 4]. </plain></SENT>
<SENT sid="353" pm="."><plain>Small sample size and the use of discrete variables (0 or 1) made multivariate analysis not feasible. </plain></SENT>
<SENT sid="354" pm="."><plain>Relating with clinical outcome, PD-L1 expression on effusion-resident PDPN+ tumor cells has significant impact on the patient's survival [risk ratio (RR) = 1.10, p = 0.011; Figure 5]. </plain></SENT>
<SENT sid="355" pm="."><plain>The likelihood ratio obtained after Cox regression analysis shows that a 1% increase of PD-L1+ PDPN+ tumor cells will increase the risk of dying with a factor of 1.10. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title><text><SENT sid="356" pm="."><plain>Dependency between chemotherapy response and the presence of CD3+CD4+ T cells after treatment </plain></SENT>
</text></title><p><text><SENT sid="357" pm="."><plain>Plot of response on chemotherapy (y-axis) versus percentage of viable CD3+CD4+ cells in the fluids after treatment (x-axis). </plain></SENT>
<SENT sid="358" pm="."><plain>Observations within our cohort are represented by the empty dots (right y-axis). </plain></SENT>
<SENT sid="359" pm="."><plain>The curve depicts the estimated probability of partial/complete response based on a univariate logistic regression model (p = 0.033; left y-axis). </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-89722-g004"/></fig></SecTag><SecTag type="FIG"><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title><text><SENT sid="360" pm="."><plain>Kaplan Meier overall survival according to percentages of PD-L1+ tumor cells present in MPM fluid samples </plain></SENT>
</text></title><p><text><SENT sid="361" pm="."><plain>The variable PD-L1+PDPN+ tumor cells (%) was divided into two groups based on the median value for the percentage of PD-L1+PDPN+ cells in our samples (median = 19.4%). </plain></SENT>
<SENT sid="362" pm="."><plain>Univariate analysis showed prognostic significance for PD-L1+PDPN+ tumor cells (p = 0.012). </plain></SENT>
<SENT sid="363" pm="."><plain>After multivariate adjustments, it remained an independent negative prognostic factor. </plain></SENT>
</text></p></caption><graphic xlink:href="oncotarget-08-89722-g005"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s3"><title><text><SENT sid="364" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="365" pm="."><plain>Our study shows different subsets of immune cells to be present in MPM pleural and ascites fluid samples. </plain></SENT>
<SENT sid="366" pm="."><plain>Although statistically not significant, we did observe differences regarding the immune constitution between both fluid types as well as within the same fluid type. </plain></SENT>
<SENT sid="367" pm="."><plain>This suggests that the immune constitution of MPM fluid samples depends on the patient rather than on the fluid type but more evidence is needed. </plain></SENT>
<SENT sid="368" pm="."><plain>The different subsets of immune cells showed distinct expression profiles for several immune checkpoints and PD-L1. </plain></SENT>
<SENT sid="369" pm="."><plain>Like the immune composition, also the expression profiles varied within the different samples as well as between the two different sample types. </plain></SENT>
</text></p><p><text><SENT sid="370" pm="."><plain>Our results confirm the study from Khanna et al. [18] that describes the presence of PD-L1+ tumor cells and both PD-1+ and PD-L1+ infiltrating immune cells in effusions of mesothelioma patients. </plain></SENT>
<SENT sid="371" pm="."><plain>The fraction of T cells expressing PD-1 varied a lot in this study (12% to 83%) which is in line with the variation seen in our own samples with a range from 9% up to 67% PD-1+ T-cells. </plain></SENT>
<SENT sid="372" pm="."><plain>They also reported basal PD-L1 expression in all their mesothelioma effusion samples with a broad range for the PD-L1 ΔMFI values, which is again in concordance with our own data. </plain></SENT>
</text></p><p><text><SENT sid="373" pm="."><plain>While PD-L1 expression in MPM tissue samples has already been reported to be associated with decreased overall survival [32, 33], as far as we know we are the first to report this for MPM fluid samples. </plain></SENT>
<SENT sid="374" pm="."><plain>Based on flow cytometric PDPN staining we found only few circulating PDPN+ tumor cells were present in ascites samples and even less were found in pleural fluids. </plain></SENT>
<SENT sid="375" pm="."><plain>Miyoshi et al. [34] made paraffin-embedded cell blocks from pleural fluids and used them for immunohistochemical staining. </plain></SENT>
<SENT sid="376" pm="."><plain>They found tumor cells in those cell blocks based on cytology, confirming our data about the presence of PDPN+ tumor cells in the fluid samples. </plain></SENT>
<SENT sid="377" pm="."><plain>Due to the tight organization of the tumor tissue as well as the surrounding mesothelial cells, tumor cells are expected not to float abundantly into patients’ effusions. </plain></SENT>
</text></p><p><text><SENT sid="378" pm="."><plain>Our data show that expression of PD-L1 on PDPN+ tumor cells in our fluid samples is a poor prognostic factor. </plain></SENT>
<SENT sid="379" pm="."><plain>Our study is limited by its small sample size which is why we used non-parametric tests for statistical analyses. </plain></SENT>
<SENT sid="380" pm="."><plain>The fact that PD-L1 expression on PDPN+ tumor cells was found to be a significant factor in our small cohort supports the need for further research in a larger cohort. </plain></SENT>
<SENT sid="381" pm="."><plain>On top of that, the prognostic value that we found for PD-L1 expression on MPM tumor cells is also supported by other studies in mesothelioma tissue samples [33, 35, 36] as well as in other cancer types [37–39]. </plain></SENT>
<SENT sid="382" pm="."><plain>Since the tumor cells express PD-L1, they might induce the expression of PD-1 and PD-L1 on surrounding immune cells via activation of the PD-1/PD-L1 pathway [40]. </plain></SENT>
<SENT sid="383" pm="."><plain>The associated decreased survival can be explained by an overstimulation of the PD-1/PD-L1 pathway leading to immune cell exhaustion with an inefficient antitumor response as final result. </plain></SENT>
<SENT sid="384" pm="."><plain>It would be interesting to investigate in future studies if the expression of PD-1 and PD-L1 in effusions might be good predictive factors for response to anti PD-1/PD-L1 blocking therapy. </plain></SENT>
</text></p><p><text><SENT sid="385" pm="."><plain>As tissue samples from MPM patients are not always available and most epithelioid mesothelioma patients develop effusions over time [1, 41], fluids might offer an alternative for a repeat biopsy for pharmacodiagnostic or prognostic purposes. </plain></SENT>
<SENT sid="386" pm="."><plain>Multi-parametric analysis of MPM fluids could then be used as an alternative for more elaborate immunohistochemistry on tissue samples for predictive (when the samples are obtained prior to treatment) and prognostic purposes. </plain></SENT>
</text></p><p><text><SENT sid="387" pm="."><plain>In addition to PD-1 and PD-L1, also the immune checkpoints TIM-3 and LAG-3 can affect the antitumor response by inhibiting lymphocyte activity. </plain></SENT>
<SENT sid="388" pm="."><plain>Therefore, investigation of immune checkpoint expression as well as immune cell profiling of the TME might be of great value to select patients who are most likely to benefit from chemo- or immunotherapy and to provide additional information on patient's outcome. </plain></SENT>
<SENT sid="389" pm="."><plain>To our knowledge, we are the first to describe the expression of TIM-3 and LAG-3 on CD4+ and CD8+ T cells and CD3-CD56+ NK cells in effusions of mesothelioma patients. </plain></SENT>
<SENT sid="390" pm="."><plain>Like PD-1 expression, we observed a considerable interpatient variation regarding the immune cell expression of TIM-3 and LAG-3. </plain></SENT>
<SENT sid="391" pm="."><plain>NK cells showed the highest expression of both markers, confirming previous MPM-unrelated reports [42–44]. </plain></SENT>
<SENT sid="392" pm="."><plain>Based on our results from MPM fluids not only TIM-3 could be an interesting target for MPM, but also LAG-3 might offer new opportunities. </plain></SENT>
<SENT sid="393" pm="."><plain>Clinical trials with TIM-3 and LAG-3 blockade in various solid tumor types are ongoing (NCT02817633; NCT02608268; NCT01968109; NCT03005782). </plain></SENT>
<SENT sid="394" pm="."><plain>Interestingly, our recent work [15] showed no expression of LAG-3 on tumor cells and immune cells in MPM tissue samples while our data in fluid samples showed its presence on T cells as well as NK cells. </plain></SENT>
<SENT sid="395" pm="."><plain>Since effusions most often occur in an inflammatory context which is known to influence the expression of immune checkpoints [45] it is quite possible that the fluid samples do not reflect the tumor microenvironment. </plain></SENT>
<SENT sid="396" pm="."><plain>Comparison of four patient-matched tissue and fluid samples demonstrates that the two milieus have a distinct immune composition and expression of immune checkpoints, which might be an explanation for the discrepancy observed between tissue and fluid samples. </plain></SENT>
<SENT sid="397" pm="."><plain>From our small sample size, it is suggested that MPM fluid samples do not have the same cellular characteristics as MPM tissue samples, which has also been suggested by Lievense et al. [46]. </plain></SENT>
<SENT sid="398" pm="."><plain>They compared the presence of T cells and macrophages in pleural effusions of 5 MPM patients with matched tissue samples and suggested that the immune cell composition of the effusions does not necessarily reflect the properties of the tumor tissue. </plain></SENT>
<SENT sid="399" pm="."><plain>Our results also confirm the presence of CD4+ T cells, CD8+ T cells and macrophages in pleural effusions of MPM patients [18–20]. </plain></SENT>
<SENT sid="400" pm="."><plain>Another explanation for the discrepancy between MPM tissue sample and effusion results for LAG-3 might be the use of different antibody clones for immunohistochemistry and flow cytometry. </plain></SENT>
<SENT sid="401" pm="."><plain>It might be that the expression levels are too low to be detected with immunohistochemistry, while the signal can be picked up by the flow cytometry antibody due to a higher sensitivity. </plain></SENT>
</text></p><p><text><SENT sid="402" pm="."><plain>In general, PD-1, TIM-3 and LAG-3 were expressed on immune cells present in the majority of pleural and ascites samples. </plain></SENT>
<SENT sid="403" pm="."><plain>Our data showed that expression of an immune checkpoint on CD4+ T cells was positively correlated with its expression on CD8+ T cells and that the expression of TIM-3 or LAG-3 on CD4+ T cells was also correlated with their expression on NK cells. </plain></SENT>
<SENT sid="404" pm="."><plain>These correlations might be explained by the close interaction between these cell types in order to elicit an antitumor immune response. </plain></SENT>
<SENT sid="405" pm="."><plain>CD4+ T cells provide help to CD8+ T cells and NK cells by secreting immunostimulatory cytokines [47–49]. </plain></SENT>
<SENT sid="406" pm="."><plain>Since expression of PD-1, TIM-3 and LAG-3 has been reported on activated immune cells [26, 50, 51], stimulation of these cells will result in an increased expression on all three cell types. </plain></SENT>
<SENT sid="407" pm="."><plain>This idea is supported by the positive correlations that we found between CD69 and PD-1 expression and between CD69 and TIM-3 expression on CD8+ T cells. </plain></SENT>
<SENT sid="408" pm="."><plain>In the evaluated patient population of cisplatin/pemetrexed-treated patients who developed effusions over time, we observed that the percentage of CD3+CD4+ T cells is significantly correlated with the patients’ response to chemotherapy. </plain></SENT>
<SENT sid="409" pm="."><plain>Since cisplatin has been reported to promote the recruitment and proliferation of immune effector cells [52], this association could be explained by cisplatin-stimulated proliferation of these cells which ultimately could result in a more effective antitumor response. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s4"><title><text><SENT sid="410" pm="."><plain>MATERIALS AND METHODS </plain></SENT>
</text></title><sec id="s4_1"><title><text><SENT sid="411" pm="."><plain>Patients and samples </plain></SENT>
</text></title><p><text><SENT sid="412" pm="."><plain>The human biological material used in this publication was provided by Biobank@UZA (Antwerp, Belgium; ID: BE71030031000; Belgian Virtual Tumorbank funded by the National Cancer Plan). </plain></SENT>
<SENT sid="413" pm="."><plain>Five ascites fluid samples and six pleural fluid samples were collected from eleven different MPM patients who received first-line chemotherapy (cisplatin + pemetrexed) at least one month before sample collection. </plain></SENT>
<SENT sid="414" pm="."><plain>Patients’ clinicopathological parameters are detailed in Table 4. </plain></SENT>
<SENT sid="415" pm="."><plain>There were no significant differences between the parameters of patients with ascites fluids and the ones with pleural fluids. </plain></SENT>
<SENT sid="416" pm="."><plain>Matched tissue samples were available from four patients and were used for immunohistochemical analysis as described previously [15]. </plain></SENT>
<SENT sid="417" pm="."><plain>This study has been approved by the Ethics Committee of the Antwerp University Hospital/University of Antwerp (EC 14/39/397). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title><text><SENT sid="418" pm="."><plain>Clinicopathological parameters of the MPM patient population </plain></SENT>
</text></title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>CHARACTERISTICS </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>PLEURAL FLUIDS (n, %) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>ASCITES FLUIDS (n, %) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>P-VALUE </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>Number of samples (N) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>0.170 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain> Median </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>66 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>61 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain> Range </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>60–73 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>41-67 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>Sex </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>0.354 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain> Male </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>6 (100%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>3 (60%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain> Female </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>2 (40%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>Histological subtype </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>0.240 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain> Epitheloid </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>3 (50%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>4 (80%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain> Sarcomatoid </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>2 (33%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain> No data </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>1 (17%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>1 (20%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>Smoker </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>1.000 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain> No </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>4 (67%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>1 (20%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain> Yes </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>2 (33%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>3 (60%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain> No data </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>1 (20%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>Professional asbestos exposure </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>/ </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain> No </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain> Yes </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>5 (83%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>3 (60%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain> No data </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>1 (17%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>2 (40%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>Survival </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>0.097 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain> Alive </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>4 (67%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain> Dead </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>2 (33%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>5 (100%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>Laterality </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>1.000 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain> Left </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>2 (33%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>2 (40%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain> Right </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>4 (67%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>3 (60%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>Stage </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>0.168 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain> I–II </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>3 (50%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain> III–IV </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>2 (33%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>5 (100%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain> No data </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>1 (17%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>Hemoglobin (g/dL) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>1.000 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain> &lt; 14.6 (low) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>4 (67%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>4 (80%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain> ≥ 14.6 (high) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>2 (33%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>1 (20%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>White blood cell count (×103 cells/ μL) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>/ </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain> &lt; 15.5 (low) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="513" pm="."><plain>6 (100%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>5 (100%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain> ≥ 15.5 (high) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>Platelet count </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>1.000 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain> &lt; 400 (low) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>4 (67%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>4 (80%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain> ≥ 400 (high) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>2 (33%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>1 (20%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="526" pm="."><plain>Neutrophil/lymphocyte ratio </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="527" pm="."><plain>0.662 </plain></SENT>
</text></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain> &lt; median♦ </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>3 (50%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>2 (40%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain> ≥ median♦ </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="532" pm="."><plain>3 (50%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="533" pm="."><plain>3 (60%) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><text><SENT sid="534" pm="."><plain>♦median of pleural fluids = 34.5; median of ascites fluids = 62.0. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec id="s4_2"><title><text><SENT sid="535" pm="."><plain>Sample collection </plain></SENT>
</text></title><p><text><SENT sid="536" pm="."><plain>Fluid samples, obtained from patients as a standard procedure for symptomatic relief, were collected via paracentesis (ascites) or thoracocentesis (pleura) in sterile tubes and filtered through a cell strainer before centrifugation. </plain></SENT>
<SENT sid="537" pm="."><plain>A Ficoll-Paque PlusTM (GE Healthcare Life Sciences, Belgium) density gradient centrifugation at 2100 rpm for 20 minutes was performed to collect the immune cells (peripheral blood mononuclear cells) and remove the red blood cells. </plain></SENT>
<SENT sid="538" pm="."><plain>After aspirating the upper layer, the layer with immune cells was transferred to a new sterile FACS tube diluted with phosphate buffered saline (PBS) and centrifuged at 1500 rpm for 5 minutes. </plain></SENT>
<SENT sid="539" pm="."><plain>Cell pellets were suspended in fetal bovine serum (FBS) supplemented with 10% dimethylsulfoxide (DMSO) and stored at liquid nitrogen until use. </plain></SENT>
</text></p></sec><sec id="s4_3"><title><text><SENT sid="540" pm="."><plain>Flow cytometry </plain></SENT>
</text></title><p><text><SENT sid="541" pm="."><plain>Frozen samples were thawed in RPMI 1640 medium supplemented with 10% FBS and 0,5% sodiumpyruvate in a 37°C warm water bath. </plain></SENT>
<SENT sid="542" pm="."><plain>Cells were counted on an ABX Micros 60 automatic cell counter (Horiba Medical, California, USA). </plain></SENT>
<SENT sid="543" pm="."><plain>Samples were analyzed for the presence of CD3+CD4+ T cells, CD3+CD8+ T cells, CD3-CD56+ NK cells, CD19+ B cells, CD64+ macrophages, CD11c+CD33+ DCs and PDPN+ tumor cells and for PD-1, PD-L1, TIM-3 and LAG-3 immune checkpoint expression using multicolor flow cytometry. </plain></SENT>
<SENT sid="544" pm="."><plain>In a first panel, combinations of PD-1-PE (clone MIH4) / LAG-3-PE (clone T47530)/ TIM-3-PE (clone 7D3), CD3-BV510, CD4-APC-H7, CD8-PB, CD69-APC and CD56-FITC (clone B159) conjugated monoclonal antibodies (mAbs) were used. </plain></SENT>
<SENT sid="545" pm="."><plain>The live/deadÒ red fixable cell stain was added to assess cell viability (Supplementary Figure 1). </plain></SENT>
<SENT sid="546" pm="."><plain>In a second panel, combinations of PD-L1-PE (clone MIH1), CD19-BV421(clone HIB19), CD64-FITC (clone 10.1), CD11c-PeCy7 (clone B-ly6) and CD303-PeCy7 (clone 201A), CD64-FITC and podoplanin-APC (PDPN, clone NZ-1.3) conjugated mAbs were used. </plain></SENT>
<SENT sid="547" pm="."><plain>A live/dead aqua fixable cell stain was added to assess cell viability (Supplementary Figure 2). </plain></SENT>
<SENT sid="548" pm="."><plain>All the antibodies were purchased from Becton Dickinson (BD Biosciencesâ), except for the live/dead stains and the CD8 mAb (Life TechnologiesTM), the CD303 mAb (Biolegendâ, California, USA) and the PDPN mAb (eBioscienceâ, Vienna, Austria). </plain></SENT>
<SENT sid="549" pm="."><plain>Corresponding species- and isotype-matched antibodies were used as controls. </plain></SENT>
<SENT sid="550" pm="."><plain>In brief, surface staining with mAbs and live/dead stain was performed for 15 minutes at room temperature, cells were washed (5 min, 1500 rpm) and resuspended in FACS buffer (sheath + 0.1% bovine serum albumine + 0.05% sodiumazide). </plain></SENT>
<SENT sid="551" pm="."><plain>Samples were acquired with FACSDiva software on a FACSAria II Beckton Dickinson flow cytometer (BD Biosciencesâ). </plain></SENT>
<SENT sid="552" pm="."><plain>Data were analyzed using FlowJo software (TreeStar inc., Ashland, USA). </plain></SENT>
<SENT sid="553" pm="."><plain>Results are expressed as ΔMFI (calculated by subtracting MFI values of isotype controls from marker MFI values) and as percentages of marker-positive cells (determined by Overton subtraction of isotype control histograms from marker histograms). </plain></SENT>
</text></p></sec><sec id="s4_4"><title><text><SENT sid="554" pm="."><plain>Statistics </plain></SENT>
</text></title><p><text><SENT sid="555" pm="."><plain>Spearman correlation coefficients were calculated to investigate the correlation between: (i) the expression of immune checkpoints and immune cell markers among the different fluid samples; (ii) the expression of immune checkpoints and immune cell markers in tissue samples and their corresponding fluid sample (n = 4); (iii) the expression of immune checkpoints and the activation marker CD69 on different subsets of effusion-resident immune cells. </plain></SENT>
<SENT sid="556" pm="."><plain>To investigate differences between ascites and pleural fluids, Wilcoxon-rank sum and Fisher exact tests were performed. </plain></SENT>
<SENT sid="557" pm="."><plain>Patients overall survival was assessed from the date of diagnosis to the date of sample analysis or the date of death. </plain></SENT>
<SENT sid="558" pm="."><plain>The influence of immunological and clinicopathological parameters on survival was assessed using Cox proportional hazards models. </plain></SENT>
<SENT sid="559" pm="."><plain>The proportional hazards assumption was tested and could not be rejected for any of the parameters under consideration. </plain></SENT>
<SENT sid="560" pm="."><plain>Response to chemotherapy was defined using the Response Evaluation Criteria in Solid Tumors (RECIST) [53]. </plain></SENT>
<SENT sid="561" pm="."><plain>The associations of the subsets of immune cells present in the fluid samples with response to chemotherapy were determined using logistic regression. </plain></SENT>
<SENT sid="562" pm="."><plain>Variable selection was performed by assessing significance on the 10% level in univariate analyses (p &lt; 0.1). </plain></SENT>
<SENT sid="563" pm="."><plain>Backward model building was used in the multivariate models for which p-values &lt; 0.05 were considered statistically significant. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec id="s5"><title><text><SENT sid="564" pm="."><plain>CONCLUSIONS </plain></SENT>
</text></title><p><text><SENT sid="565" pm="."><plain>With this study, we show a patient-dependent inter- and intraspecific variation for both the immune cell composition and immune checkpoint expression in pleural versus ascites MPM effusions. </plain></SENT>
<SENT sid="566" pm="."><plain>Nevertheless, PD-1, PD-L1, TIM-3 and LAG-3 are expressed in the majority of effusion samples, thereby identifying TIM-3 and LAG-3 as potential novel targets in MPM. </plain></SENT>
<SENT sid="567" pm="."><plain>Our data describe two MPM effusion-related factors with clinical value. </plain></SENT>
<SENT sid="568" pm="."><plain>The percentage of CD4+ T cells present in the effusions is significantly correlated with response to chemotherapy, while the percentage of PD-L1+ PDPN+ tumor cells can be translated as a significant prognostic factor for worse outcome. </plain></SENT>
<SENT sid="569" pm="."><plain>The results of this study provide more insight in the cellular composition of MPM effusions and support further elaborate research on MPM effusions for the identification of biomarkers and the development of immune checkpoint-targeted immunotherapy. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s6"><title><text><SENT sid="570" pm="."><plain>SUPPLEMENTARY MATERIALS FIGURES AND TABLES </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-08-89722-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e2059" position="anchor"/></supplementary-material></sec></SecTag></body><back><fn-group><SecTag type="AUTH_CONT"><fn fn-type="con"><p><text><SENT sid="571" pm="."><plain>Author contributions </plain></SENT>
</text></p><p><text><SENT sid="572" pm="."><plain>EM designed and performed experiments, analyzed data and wrote the manuscript. </plain></SENT>
<SENT sid="573" pm="."><plain>ES designed experiments and revised manuscript. </plain></SENT>
<SENT sid="574" pm="."><plain>ES, PP and JvM supervised research and drafted paper. </plain></SENT>
<SENT sid="575" pm="."><plain>JVA and JDW assisted with experiments, contributed to the analysis and interpretation of data. </plain></SENT>
<SENT sid="576" pm="."><plain>EL, NH and ES contributed to the analysis and interpretation of data. </plain></SENT>
<SENT sid="577" pm="."><plain>All authors contributed to the final version of the manuscript. </plain></SENT>
</text></p></fn></SecTag></fn-group><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="578" pm="."><plain>The authors would like to acknowledge the Tumor Biobank from the Department of Pathology at the Antwerp University Hospital for providing MPM patient samples. </plain></SENT>
<SENT sid="579" pm="."><plain>They also want to express their gratitude to Dr. Paul Van Schil from the Department of Thoracic and Vascular Surgery at the Antwerp University Hospital for collecting the patient samples. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="580" pm="."><plain>CONFLICTS OF INTEREST </plain></SENT>
</text></p><p><text><SENT sid="581" pm="."><plain>The authors have no conflicts of interest to declare. </plain></SENT>
</text></p></fn><fn fn-type="supported-by"><p><text><SENT sid="582" pm="."><plain>FUNDING </plain></SENT>
</text></p><p><text><SENT sid="583" pm="."><plain>This work was performed with the support of the Belgian Foundation Against Cancer (grant number: FA/2014/263), the Research Foundation Flanders (grant number: 1510215N), AstraZeneca and a Methusalem grant of the University of Antwerp and Hasselt awarded to Prof. </plain></SENT>
<SENT sid="584" pm="."><plain>Herman Goossens and Prof Geert Molenberghs. </plain></SENT>
<SENT sid="585" pm="."><plain>E. </plain></SENT>
<SENT sid="586" pm="."><plain>Marcq is a research fellow of Flanders Innovation &amp; Entrepreneurship (fellowship number: 141433), J. </plain></SENT>
<SENT sid="587" pm="."><plain>De Waele and J. </plain></SENT>
<SENT sid="588" pm="."><plain>Van Audenaerde of the Research Foundation Flanders (fellowship numbers: 1121016N and 1S32316N). </plain></SENT>
</text></p></fn></fn-group><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>CD</term><def><p>Cluster of differentiation</p></def></def-item><def-item><term>CTLA-4</term><def><p>Cytotoxic T lymphocyte antigen-4</p></def></def-item><def-item><term>DC</term><def><p>Dendritic cell</p></def></def-item><def-item><term>DMSO</term><def><p>Dimethylsulfoxide</p></def></def-item><def-item><term>FBS</term><def><p>Fetal bovine serum</p></def></def-item><def-item><term>FDA</term><def><p>Food and drug administration</p></def></def-item><def-item><term>LAG-3</term><def><p>Lymphocyte activation gene-3</p></def></def-item><def-item><term>mAb</term><def><p>Monoclonal antibody</p></def></def-item><def-item><term>MFI</term><def><p>Mean fluorescence intensity</p></def></def-item><def-item><term>MPM</term><def><p>Malignant pleural mesothelioma</p></def></def-item><def-item><term>NK</term><def><p>Natural killer</p></def></def-item><def-item><term>PBS</term><def><p>Phosphate buffered saline</p></def></def-item><def-item><term>PD-1</term><def><p>Programmed death-1</p></def></def-item><def-item><term>PD-L1</term><def><p>Programmed death-ligand 1</p></def></def-item><def-item><term>PDPN</term><def><p>Podoplanin</p></def></def-item><def-item><term>RECIST</term><def><p>Response evaluation criteria in solid tumors</p></def></def-item><def-item><term>TIM-3</term><def><p>T cell immunoglobulin mucin-3</p></def></def-item><def-item><term>TME</term><def><p>Tumor microenvironment</p></def></def-item></def-list></glossary></SecTag><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="R1"><text><SENT sid="589" pm="."><plain>1RobinsonBWMuskAWLakeRAMalignant mesotheliomaLancet2005366397408<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(05)67025-0">https://doi.org/10.1016/S0140-6736(05)67025-0</ext-link>16054941 </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="590" pm="."><plain>2StaynerLWelchLSLemenRThe worldwide pandemic of asbestos-related diseasesAnnu Rev Public Health20133420516<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1146/annurev-publhealth-031811-124704">https://doi.org/10.1146/annurev-publhealth-031811-124704</ext-link>23297667 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="591" pm="."><plain>3RobinsonBWLakeRAAdvances in malignant mesotheliomaN Engl J Med20053531591603<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMra050152">https://doi.org/10.1056/NEJMra050152</ext-link>16221782 </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="592" pm="."><plain>4van MeerbeeckJPGaafarRManegoldCVan KlaverenRJVan MarckEAVincentMLegrandCBottomleyADebruyneCGiacconeGRandomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of CanadaJ Clin Oncol20052368819<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.20005.14.589">https://doi.org/10.1200/JCO.20005.14.589</ext-link>16192580 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="593" pm="."><plain>5VogelzangNJRusthovenJJSymanowskiJDenhamCKaukelERuffiePGatzemeierUBoyerMEmriSManegoldCNiyikizaCPaolettiPPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321263644<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2003.11.136">https://doi.org/10.1200/JCO.2003.11.136</ext-link>12860938 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="594" pm="."><plain>6BagiaMNowakAKNovel targeted therapies and vaccination strategies for mesotheliomaCurr Treat Options Oncol20111214962<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11864-011-0149-1">https://doi.org/10.1007/s11864-011-0149-1</ext-link>21424750 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="595" pm="."><plain>7IzziVMasuelliLTresoldiIFotiCModestiABeiRImmunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapiesCancer Lett20123221834<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.canlet.2012.02.034">https://doi.org/10.1016/j.canlet.2012.02.034</ext-link>22394996 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="596" pm="."><plain>8CornelissenRHeuversMEMaatAPHendriksRWHoogstedenHCAertsJGHegmansJPNew roads open up for implementing immunotherapy in mesotheliomaClin Dev Immunol20122012927240<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2012/927240">https://doi.org/10.1155/2012/927240</ext-link>22778767 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="597" pm="."><plain>9AlleyEWLopezJSantoroAMoroskyASarafSPiperdiBvan BrummelenEClinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trialLancet Oncol2017<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1470-2045(17)30169-9">https://doi.org/10.1016/S1470-2045(17)30169-9</ext-link> </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="598" pm="."><plain>10CalabroLMorraAFonsattiECutaiaOAmatoGGiannarelliDDi GiacomoAMDanielliRAltomonteMMuttiLMaioMTremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialLancet Oncol201314110411<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1470-2045(13)70381-4">https://doi.org/10.1016/S1470-2045(13)70381-4</ext-link>24035405 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="599" pm="."><plain>11CalabroLMorraAFonsattiECuataiaOFazioCDanielliRGiannarelliDAltomonteMDi GiacomoAMMaioMA phase 2 single-arm study with tremelimumab at an optimized doseing schedule in second-line mesothelioma patientsJ ClinOncol2014325s </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="600" pm="."><plain>12HassanRThomasAPatelMRNemunaitisJJBennouanaJPowderlyJDTaylorMHDowlatiAChenFLeachJVaishampayanUNVerschraegenCFDelordJPAvelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expressionJ Clin Oncol201634 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="601" pm="."><plain>13JanssenJQZagoGSchoutenRBuikhuisenWMonkhorstKThunissenEBaasPA phase II study of Nivolumab in malignant pleural mesothelioma (NIVOMES): with translational research (TR) biopsiesJ Thor Oncol201712S292293<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtho.2016.11.300">http://dx.doi.org/10.1016/j.jtho.2016.11.300</ext-link> </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="602" pm="."><plain>14MaioMScherpereelADi PietroAVaseyPTsaoASCalabrïLFuDRobbinsPBIbrahimRAKindlerHLRandomized, double-blind, placebo-controlled study of tremelimumab for second and third-line treatment of unresectable pleural or peritoneal mesotheliomaJ Clin Oncol2014325s </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="603" pm="."><plain>15MarcqESiozopoulouVDe WaeleJvan AudenaerdeJZwaenepoelKSantermansEHensNPauwelsPvan MeerbeeckJPSmitsELPrognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesotheliomaOncoimmunology20176e1261241<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/2162402X.2016.1261241">https://doi.org/10.1080/2162402X.2016.1261241</ext-link>28197385 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="604" pm="."><plain>16StathopoulosGTKalomenidisIMalignant pleural effusion: tumor-host interactions unleashedAm J Respir Crit Care Med201218648792<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1164/rccm.201203-0465PP">https://doi.org/10.1164/rccm.201203-0465PP</ext-link>22652027 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="605" pm="."><plain>17CheneALd’AlmeidaSBlondyTTabiascoJDeshayesSFonteneauJFCellerinLDelnesteYGregoireMBlanquartCPleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 MacrophagesJ Thorac Oncol201611176573<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtho.2016.06.022">https://doi.org/10.1016/j.jtho.2016.06.022</ext-link>27418105 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="606" pm="."><plain>18KhannaSThomasAAbate-DagaDZhangJMorrowBSteinbergSMOrlandiAFerroniPSchlomJGuadagniFHassanRMalignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody AvelumabJ Thorac Oncol20161119932005<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtho.2016.07.033">https://doi.org/10.1016/j.jtho.2016.07.033</ext-link>27544053 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="607" pm="."><plain>19LievenseLACornelissenRBezemerKKaijen-LambersMEHegmansJPAertsJGPleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell SuppressionJ Thorac Oncol201611175564<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtho.2016.06.021">https://doi.org/10.1016/j.jtho.2016.06.021</ext-link>27418106 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="608" pm="."><plain>20ScherpereelAGrigoriuBDNoppenMGeyTChahineBBaldacciSTrauetJCopinMCDessaintJPPorteHLabaletteMDefect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluidBMC Cancer201313324<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2407-13-324">https://doi.org/10.1186/1471-2407-13-324</ext-link>23816056 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="609" pm="."><plain>21GoldbergMVDrakeCGLAG-3 in Cancer ImmunotherapyCurr Top Microbiol Immunol201134426978<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/82_2010_114">https://doi.org/10.1007/82_2010_114</ext-link>21086108 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="610" pm="."><plain>22Macon-LemaitreLTriebelFThe negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cellsImmunology20051151708<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1365-2567.2005.02145.x">https://doi.org/10.1111/j.1365-2567.2005.02145.x</ext-link>15885122 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="611" pm="."><plain>23WorkmanCJVignaliDANegative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)J Immunol200517468895<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.174.2.688">https://doi.org/10.4049/jimmunol.174.2.688</ext-link>15634887 </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="612" pm="."><plain>24NgiowSFvon ScheidtBAkibaHYagitaHTengMWSmythMJAnti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumorsCancer Res201171354051<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-11-0096">https://doi.org/10.1158/0008-5472.CAN-11-0096</ext-link>21430066 </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="613" pm="."><plain>25FourcadeJKudelaPAndrade FilhoPAJanjicBLandSRSanderCKriegADonnenbergAShenHKirkwoodJMZarourHMImmunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patientsJ Immunother20083178191<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/CJI.0b013e318183af0b">https://doi.org/10.1097/CJI.0b013e318183af0b</ext-link>18779741 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="614" pm="."><plain>26MonneyLSabatosCAGagliaJLRyuAWaldnerHChernovaTManningSGreenfieldEACoyleAJSobelRAFreemanGJKuchrooVKTh1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature200241553641<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/415536a">https://doi.org/10.1038/415536a</ext-link>11823861 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="615" pm="."><plain>27AndersonACAndersonDEBregoliLHastingsWDKassamNLeiCChandwaskarRKarmanJSuEWHirashimaMBruceJNKaneLPKuchrooVKPromotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cellsScience200731811413<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1148536">https://doi.org/10.1126/science.1148536</ext-link>18006747 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="616" pm="."><plain>28HannaAPangYBedrossianCWDejmekAMichaelCWPodoplanin is a useful marker for identifying mesothelioma in malignant effusionsDiagn Cytopathol201038264920146302 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="617" pm="."><plain>29KimuraNKimuraIPodoplanin as a marker for mesotheliomaPathol Int20055583615693854 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="618" pm="."><plain>30YamakiEYajimaTKosakaTMogiATanakaSKuwanoHPodoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotypeOncol Rep2013299324023291918 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="619" pm="."><plain>31TakeuchiSFukudaKYamadaTAraiSTakagiSIshiiGOchiaiAIwakiriSItoiKUeharaHNishiharaHFujitaNYanoSPodoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formationCancer Sci201710869670328182302 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="620" pm="."><plain>32MansfieldASRodenACPeikertTSheininYMHarringtonSMKrcoCJDongHKwonEDB7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosisJ Thorac Oncol20149103640<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/JTO.0000000000000177">https://doi.org/10.1097/JTO.0000000000000177</ext-link>24926549 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="621" pm="."><plain>33CedresSPonce-AixSZugazagoitiaJSansanoIEnguitaANavarro-MendivilAMartinez-MartiAMartinezPFelipEAnalysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)PLoS One201510e0121071<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0121071">https://doi.org/10.1371/journal.pone.0121071</ext-link>25774992 </plain></SENT>
</text></ref><ref id="R34"><text><SENT sid="622" pm="."><plain>34MiyoshiSSasadaSIzumoTMatsumotoYTsuchidaTDiagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective AnalysisPLoS One201611e0167186<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0167186">https://doi.org/10.1371/journal.pone.0167186</ext-link>27880851 </plain></SENT>
</text></ref><ref id="R35"><text><SENT sid="623" pm="."><plain>35CurrieAJProsserAMcDonnellACleaverALRobinsonBWFreemanGJvan der MostRGDual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulationJ Immunol20091837898908<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.0901060">https://doi.org/10.4049/jimmunol.0901060</ext-link>20007574 </plain></SENT>
</text></ref><ref id="R36"><text><SENT sid="624" pm="."><plain>36YamadaNOizumiSKikuchiEShinagawaNKonishi-SakakibaraJIshimineAAoeKGembaKKishimotoTTorigoeTNishimuraMCD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resectionCancer Immunol Immunother20105915439<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00262-010-0881-6">https://doi.org/10.1007/s00262-010-0881-6</ext-link>20567822 </plain></SENT>
</text></ref><ref id="R37"><text><SENT sid="625" pm="."><plain>37HinoRKabashimaKKatoYYagiHNakamuraMHonjoTOkazakiTTokuraYTumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanomaCancer2010116175766<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cncr.24899">https://doi.org/10.1002/cncr.24899</ext-link>20143437 </plain></SENT>
</text></ref><ref id="R38"><text><SENT sid="626" pm="."><plain>38HamanishiJMandaiMIwasakiMOkazakiTTanakaYYamaguchiKHiguchiTYagiHTakakuraKMinatoNHonjoTFujiiSProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerProc Natl Acad Sci USA200710433605<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.0611533104">https://doi.org/10.1073/pnas.0611533104</ext-link>17360651 </plain></SENT>
</text></ref><ref id="R39"><text><SENT sid="627" pm="."><plain>39ThompsonRHKuntzSMLeibovichBCDongHLohseCMWebsterWSSenguptaSFrankIParkerASZinckeHBluteMLSeboTJChevilleJCTumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-upCancer Res2006663381516585157 </plain></SENT>
</text></ref><ref id="R40"><text><SENT sid="628" pm="."><plain>40MarcqEPauwelsPvan MeerbeeckJPSmitsELTargeting immune checkpoints: New opportunity for mesothelioma treatment?Cancer Treat Rev20154191424<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ctrv.2015.09.006">https://doi.org/10.1016/j.ctrv.2015.09.006</ext-link>26433514 </plain></SENT>
</text></ref><ref id="R41"><text><SENT sid="629" pm="."><plain>41VogelzangNJSchultzSMIannucciAMKennedyBJMalignant mesothelioma. </plain></SENT>
<SENT sid="630" pm="."><plain>The University of Minnesota experienceCancer198453377836692252 </plain></SENT>
</text></ref><ref id="R42"><text><SENT sid="631" pm="."><plain>42BaixerasEHuardBMiossecCJitsukawaSMartinMHercendTAuffrayCTriebelFPiatier-TonneauDCharacterization of the lymphocyte activation gene 3-encoded protein. </plain></SENT>
<SENT sid="632" pm="."><plain>A new ligand for human leukocyte antigen class II antigensJ Exp Med199217632737<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1084/jem.176.2.327">https://doi.org/10.1084/jem.176.2.327</ext-link>1380059 </plain></SENT>
</text></ref><ref id="R43"><text><SENT sid="633" pm="."><plain>43WorkmanCJVignaliDAThe CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cellsEur J Immunol2003339709<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/eji.200323382">https://doi.org/10.1002/eji.200323382</ext-link>12672063 </plain></SENT>
</text></ref><ref id="R44"><text><SENT sid="634" pm="."><plain>44GleasonMKLenvikTRMcCullarVFelicesMO’BrienMSCooleySAVernerisMRCichockiFHolmanCJPanoskaltsis-MortariANikiTHirashimaMBlazarBRTim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9Blood2012119306472<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2011-06-360321">https://doi.org/10.1182/blood-2011-06-360321</ext-link>22323453 </plain></SENT>
</text></ref><ref id="R45"><text><SENT sid="635" pm="."><plain>45PsallidasIKalomenidisIPorcelJMRobinsonBWStathopoulosGTMalignant pleural effusion: from bench to bedsideEur Respir Rev20162518998<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1183/16000617.0019-2016">https://doi.org/10.1183/16000617.0019-2016</ext-link>27246596 </plain></SENT>
</text></ref><ref id="R46"><text><SENT sid="636" pm="."><plain>46LievenseLABezemerKCornelissenRKaijen-LambersMEHegmansJPAertsJGPrecision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patientsLung Cancer20171073640<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lungcan.2016.04.015">https://doi.org/10.1016/j.lungcan.2016.04.015</ext-link>27168021 </plain></SENT>
</text></ref><ref id="R47"><text><SENT sid="637" pm="."><plain>47ZhuJPaulWECD4 T cells: fates, functions, and faultsBlood2008112155769<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2008-05-078154">https://doi.org/10.1182/blood-2008-05-078154</ext-link>18725574 </plain></SENT>
</text></ref><ref id="R48"><text><SENT sid="638" pm="."><plain>48NeurathMFFinottoSThe emerging role of T cell cytokines in non-small cell lung cancerCytokine Growth Factor Rev20122331522<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cytogfr.2012.08.009">https://doi.org/10.1016/j.cytogfr.2012.08.009</ext-link>23022528 </plain></SENT>
</text></ref><ref id="R49"><text><SENT sid="639" pm="."><plain>49FriedmanKMPrietoPADevillierLEGrossCAYangJCWunderlichJRRosenbergSADudleyMETumor-specific CD4+ melanoma tumor-infiltrating lymphocytesJ Immunother2012354008<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/CJI.0b013e31825898c5">https://doi.org/10.1097/CJI.0b013e31825898c5</ext-link>22576345 </plain></SENT>
</text></ref><ref id="R50"><text><SENT sid="640" pm="."><plain>50FranciscoLMSagePTSharpeAHThe PD-1 pathway in tolerance and autoimmunityImmunol Rev201023621942<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-065X.2010.00923.x">https://doi.org/10.1111/j.1600-065X.2010.00923.x</ext-link>20636820 </plain></SENT>
</text></ref><ref id="R51"><text><SENT sid="641" pm="."><plain>51HemonPJean-LouisFRamgolamKBrignoneCViguierMBachelezHTriebelFCharronDAoudjitFAl-DaccakRMichelLMHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosisJ Immunol2011186517383<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.1002050">https://doi.org/10.4049/jimmunol.1002050</ext-link>21441454 </plain></SENT>
</text></ref><ref id="R52"><text><SENT sid="642" pm="."><plain>52de BiasiARVillena-VargasJAdusumilliPSCisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidenceClin Cancer Res201420538491<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/1078-0432.CCR-14-1298">https://doi.org/10.1158/1078-0432.CCR-14-1298</ext-link>25204552 </plain></SENT>
</text></ref><ref id="R53"><text><SENT sid="643" pm="."><plain>53HoosAEggermontAMJanetzkiSHodiFSIbrahimRAndersonAHumphreyRBlumensteinBOldLWolchokJImproved endpoints for cancer immunotherapy trialsJ Natl Cancer Inst2010102138897<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jnci/djq310">https://doi.org/10.1093/jnci/djq310</ext-link>20826737 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
